Blood Glucose Control

Woman, 64 years of age. History of Class II Obesity and hyperlipidemia. While she had obesity, her glucose levels were elevated. A1C 8.2%. She followed a lower carb meal plan, was active, took metformin and a GLP-1, a statin and an ACE-I. She lost 22% total body weight. A1C then remained in the 6-6.5% range for 3 years on this treatment plan. Over the past 8 months, due to insurance and her statement of denial that she ever really had diabetes, she stopped taking her glucose-lowering medication, statin, and ACE-I, wasn’t as strict with meal plan or activity, and stopped checking her glucose, but did not gain back her weight.

In part 2 of this exclusive ADA interview, Anthony Cincotta discusses the Cycloset Safety Trial study design and findings regarding the cardiovascular safety of Cycloset.

A single, once-daily injection to lower both fasting and postprandial blood glucose

Are clinicians intensifying treatment before it is too late?

Study could not evaluate drug's long-term effects on diabetes prevention, length of effects

Is A1c better than an Oral Glucose Tolerance Test in diabetes management?

What benefits can lixisenatide provide when added to basal insulin regimen?

Could GLP-1 inhibitors be a useful adjunct therapy in type I diabetes?

Tighter glucose and blood pressure control found to decrease incidence.

A phase 2 randomized controlled trial demonstrated clinically significant changes in glycemic control.